Frequency of EGFR Mutations in Non-small Cell Lung Cancer Patients: Screening Data from West Siberia

Abstract

Background: Incorporation of molecular analysis of the epidermal growth factor receptor (EGFR) gene into routine clinical practice has shown great promise to provide personalized therapy of the non-small cell lung cancer (NSCLC) in the developed world. However, the genetic testing of EGFR mutations has not yet become routine clinical practice in territories remote from the central regions of Russia. Therefore, we aimed to study the frequency of major types of activating mutations of the EGFR gene in NSCLC patients residing in West Siberia. Materials and Methods: We examined EGFR mutations in exons 19 and 21 in 147 NSCLC patients (excluding squamous cell lung carcinomas) by real time polymerase chain reaction. Results: EGFR mutations were detected in 28 of the 147 (19%) patients. There were 19 (13%) cases with mutations in exon 19 and 9 cases (6%) in exon 21. Mutations were more frequently observed in women (42%, p=0.000) than in men (1%). A significantly higher incidence of EGFR mutations was observed in bronchioloalveolar carcinomas (28%, p=0.019) and in adenocarcinomas (21%, p=0.024) than in large cell carcinomas, mixed adenocarcinomas, and NOS (4%). The EGFR mutation rate was much higher in never-smokers than in smokers: 38% vs. 3% (p=0.000). The frequency of EGFR mutations in the Kemerovo and Tomsk regions was 19%. Conclusions: The incorporation of molecular analysis of the EGFR gene into routine clinical practice will allow clinicians to provide personalised therapy, resulting in a significant increase in survival rates and improvement in life quality of advanced NSCLC patients.

Epidermal Growth Factor Receptor Mutation Frequency in Squamous Cell Carcinoma and Its Diagnostic Performance in Cytological Samples: A Molecular and Immunohistochemical Study

“…Han et al reported 9.9% and 3.7% EGFR mutation in SCC and 49.3% and 18% mutation in adenocarcinoma from Asia-Pacific region and Russia respectively [3]. EGFR mutation in SCC varies between 0-25% in different regions of the world [6, 29, 31].…”

Methods for Early Detection of Lung Cancer (Review)

“…Начало лечения на ранних стадиях позволяет существенно увеличить шансы пациента на выздоровление и быстрейшую социальную и трудовую адаптацию. При этом пятилетняя выживаемость после лечения I стадии составляет 70 %, а IV стадии -менее 5 % [3,4].…”

In silico insight into EGFR treatment in patients with lung carcinoma and T790M mutations

“…Other than genetic factors, patient characteristics including gender, race and lifestyle influence the effectiveness of the treatment for NSCLC ( 5 ). The most prominent genetic factor associated with the responsiveness to NSCLC treatment is a mutation in EGFR ( 6 , 7 ). Mutations in EGFR mediate the carcinogenic effect by manipulating the apoptotic mechanism ( 8 ).…”